IPP Bureau
Tulasi Healthcare Introduces dTMS Therapy service for Treatment-Resistant Depression
By IPP Bureau - August 16, 2023
Deep Transcranial Magnetic Stimulation (dTMS) is a non-invasive brain stimulation technique approved by regulatory authorities, including the USFDA
Exor to buy 15% shareholding in Philips
By IPP Bureau - August 16, 2023
Exor’s investment in Philips will not result in any share dilution and has been carried out by way of on-market share purchases
BioNTech appointing James Ryan as Chief Legal Officer
By IPP Bureau - August 16, 2023
Ryan has nearly 20 years of global legal and IP expertise in the pharmaceutical industry
Boehringer Ingelheim receives FDA approval for Senvelgo to treat diabetes in cat
By IPP Bureau - August 16, 2023
Senvelgo is the first liquid once-daily, orally administered prescription medication to improve glycemic control in cats with diabetes mellitus
Dr Srikanth Ramaswamy bags Lister Prize to fund brain research
By IPP Bureau - August 16, 2023
Newcastle University’s Dr Srikanth Ramaswamy has been announced as one of six new Fellows selected for the 2023 Lister prize
Parexel and Partex collaborate to leverage on AI and Big Data to accelerate drug delivery
By IPP Bureau - August 16, 2023
Collaboration combines clinical research expertise with artificial intelligence capabilities to help drug developers better understand the probability of clinical success for their assets
Eugia Pharma receives USFDA Approval for Icatibant Injection
By IPP Bureau - August 16, 2023
This is the 166th ANDA out of Eugia Pharma Speciality Group facilities
National Medical Library has a pivotal role to play in making medical education accessible to all via digital platform: Dr Pawar
By IPP Bureau - August 14, 2023
Continuous learning is not just an option but a responsibility that every healthcare professional must shoulder
Aurobindo Pharma reports Q1 FY24 consolidated PAT at Rs. 570.75 Cr
By IPP Bureau - August 13, 2023
Aurobindo Pharma has reported total income of Rs. 6966.85 crores during the period ended June 30, 2023
Krsnaa Diagnostics posts Q1 FY24 consolidated PAT at Rs. 14.64 Cr
By IPP Bureau - August 13, 2023
Krsnaa Diagnostics has reported total income of Rs. 143.80 crores during the period ended June 30, 2023
Panacea Biotec posts Q1 FY24 consolidated PAT at Rs. 10.98 Cr
By IPP Bureau - August 13, 2023
Panacea Biotec has reported total income of Rs. 135.27 crores during the period ended June 30, 2023
LyondellBasell awarded the 2023 Global Medical Plastics Company of the year
By IPP Bureau - August 13, 2023
LyondellBasell is among the top three global polyolefin manufacturers in terms of capacity and sustainable solutions
WuXi XDC and Boostimmune sign MoU for integrated services
By IPP Bureau - August 13, 2023
Boostimmune will have access to WuXi XDC's fully integrated one-stop bioconjugate platform
Gujarat Themis Biosyn posts Q1 FY24 PAT at Rs. 17.72 Cr
By IPP Bureau - August 12, 2023
Gujarat Themis Biosyn has reported total income of Rs. 50.66 crores during the period ended June 30, 2023
IPCA Laboratories posts Q1 FY24 consolidated PAT at Rs. 162.82 Cr
By IPP Bureau - August 12, 2023
IPCA Laboratories has reported total income of Rs. 1632.43 crores during the period ended June 30, 2023
